ArticleHaematologica2018
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.
Abstract readLetter
In one paragraph
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.Frontiers in pharmacology · 2024Review
- Heat shock protein 90 inhibition attenuates inflammation in models of atopic dermatitis: a novel mechanism of action.Frontiers in immunology · 2023Article
- Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.Cell stress & chaperones · 2022Article
- Review
- SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2021Review
- Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.Haematologica · 2021Review
- HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.Blood cancer journal · 2021Article
- Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
- Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms.Cancers · 2020Review
- Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy.Cancers · 2019Review
- New Concepts of Treatment for Patients with Myelofibrosis.Current treatment options in oncology · 2019Review
- JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Gabriela S HobbsDivision of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, USA.
Amritha Varshini Hanasoge SomasundaraHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA.
Maria KleppeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA.
Rivka LitvinLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
Maria ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, USA.
Jihae AhnDriskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University, USA.
Anna Sophia McKenneyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA.
Kristina KnappCenter for Epigenetics Research Memorial Sloan Kettering Center, USA.
Ryan PtashkinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, USA.
Howard WeinsteinCardiology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, USA.
Murk-Hein HeinemannDepartment of Surgery, Memorial Sloan Kettering Cancer Center, USA.
Jasmine FrancisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, USA.
Suzanne ChanelLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
Ellin BermanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
Michael MauroLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA.
Mark L HeaneyDepartment of Medicine, Columbia University Medical Center, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, USA.
Raajit K RampalLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA rampalr@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MWeill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1MDana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MGenomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RAMPAL, RAAJIT · 2014 to 2018
$891kRole of aberrant cytokine signaling in myeloproliferative disordersK99HL122503 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KLEPPE, MARIA · 2016 to 2017
$275kModeling Transformation: Myeloproliferative Neoplasms to Acute Myeloid LeukemiaF30CA183497 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MCKENNEY, ANNA SOPHIA · 2014 to 2017
$193kNCI NIH HHS K08 CA188529NCI NIH HHS K12 CA087723NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA173636NHLBI NIH HHS K99 HL122503NIGMS NIH HHS T32 GM007739
Abstract
PubMed holds no abstract for this paper.
Indexed as
Clinical Trials, Phase II as TopicHSP90 Heat-Shock ProteinsHumansJanus KinasesMolecular Targeted TherapyMyeloproliferative DisordersSignal TransductionSplenomegalySTAT Transcription FactorsTreatment OutcomeHSP90 Heat-Shock ProteinsJanus KinasesSTAT Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.